| # | Drug | Count |
|---|---|---|
| 0 | PREDNISONE | 565 |
| 1 | SARILUMAB | 228 |
| 2 | ALENDRONATE SODIUM | 212 |
| 3 | METHOTREXATE SODIUM | 206 |
| 4 | ATORVASTATIN CALCIUM | 199 |
| 5 | ERGOCALCIFEROL | 191 |
| 6 | PEMBROLIZUMAB | 184 |
| 7 | METFORMIN | 176 |
| 8 | METHOTREXATE | 175 |
| 9 | ASPIRIN | 174 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DENOSUMAB-BMWO | 2 | 0.0606 |
| 1 | ACLIDINIUM BROMIDE | 84 | 0.0131 |
| 2 | PIMOZIDE | 5 | 0.0104 |
| 3 | AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE | 1 | 0.0085 |
| 4 | CROVALIMAB | 1 | 0.0083 |
| 5 | SARILUMAB | 228 | 0.0082 |
| 6 | ALENDRONATE SODIUM AND CHOLECALCIFEROL | 21 | 0.0076 |
| 7 | BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | 3 | 0.0067 |
| 8 | TOCILIZUMAB-AAZG | 4 | 0.0065 |
| 9 | ERGOCALCIFEROL | 191 | 0.0064 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 796 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 351 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 339 |
| 3 | Interleukin-6 Receptor Antagonist [EPC] | 315 |
| 4 | HMG-CoA Reductase Inhibitor [EPC] | 286 |
| 5 | Provitamin D2 Compound [EPC] | 191 |
| 6 | Benzodiazepine [EPC] | 189 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 189 |
| 8 | Loop Diuretic [EPC] | 181 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 175 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 69 | 0.1003 |
| 1 | Complement C5 Inhibitor [EPC] | 1 | 0.0083 |
| 2 | Provitamin D2 Compound [EPC] | 191 | 0.0064 |
| 3 | Lymphocyte Activation Gene-3 Blocker [EPC] | 3 | 0.0058 |
| 4 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 339 | 0.0034 |
| 5 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 2 | 0.0033 |
| 6 | Interleukin-6 Receptor Antagonist [EPC] | 315 | 0.0023 |
| 7 | PCSK9 Inhibitor [EPC] | 47 | 0.0018 |
| 8 | Programmed Death Ligand-1 Blocker [EPC] | 32 | 0.0015 |
| 9 | Interleukin-17 Receptor A Antagonist [EPC] | 3 | 0.0015 |